Who is sponsoring SAFIR?

SAFIR is sponsored by University of Aarhus.

What condition does SAFIR study?

SAFIR studies Kidney Failure, Chronic.

What drugs are being tested in SAFIR?

Interventions: Irbesartan, Placebo matching irbesartan 150 mg.

Last reviewed 2013-01-07 · How we verify

Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan - a Double Blind Randomised Study (SAFIR)

NCT00791830 Phase 3 COMPLETED

Angiotensin II receptor blockers (ARB) are known to preserve kidney function among patients with kidney diseases and reduced renal function, but not among haemodialysis patients. Haemodialysis patients often lose residual renal function after initiating dialysis leading to worsened quality of life, increased morbidity and mortality. In this study an ARB is investigated in a double blind, randomised, parallel group, placebo controlled manner to see, if this ARB can save residual renal function among haemodialysis patients. Potential cardiovascular benefits of the treatment are also addressed.

Details

Lead sponsor	University of Aarhus
Phase	Phase 3
Status	COMPLETED
Enrolment	82
Start date	2009-04
Completion	2013-01

Conditions

Kidney Failure, Chronic

Interventions

Irbesartan
Placebo matching irbesartan 150 mg

Primary outcomes

Decrease in loss of residual kidney function. — 3, 6, 9 and 12 months

Countries

Denmark